Bisantrene gets a few mentions (FTO MODULATION) in this review of research on metabolism-targeted therapy and immunotherapy. Mason level technical...but we get a wrap...
"Subsequently, more potent inhibitors with potential to improveanti-tumor immunity was developed. CS1/2-induced FTO inhibition not only attenuates leukemia stem cell self-renewal, but reprograms immune responses"
Good to know that while we have some shorter term therapy and revenue possibilities, we also have another iron in the fire in this emerging new area.
Bisnatrene Therapy=
Cancer Killing
Cardio Protecting
Immunotherapy Enhancing
FTO-CS1-CS2-IMMUNOTHERAPY.pdf
Bisantrene gets a few mentions (FTO MODULATION) in this review...
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.31 |
Change
0.020(1.55%) |
Mkt cap ! $217.2M | |||
| Open | High | Low | Value | Volume |
| $1.31 | $1.31 | $1.26 | $71.25K | 55.65K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 200 | $1.27 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.31 | 5950 | 3 |
View Market Depth
| Last trade - 16.10pm 26/04/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.31 |
Change
0.020 ( 2.18 %) |
||||
| Open | High | Low | Volume | ||
| $1.30 | $1.31 | $1.26 | 10789 | ||
| Last updated 15.59pm 26/04/2024 ? | |||||
| RAC (ASX) Chart |